Twelve Months Dual Antiplatelet Therapy after Drug-eluting Stents – Too Long, too Short or Just Right?


Dual Antiplatelet Therapy (DAPT) remains a cornerstone in the secondary prevention of coronary artery disease. Further, in contemporary practice, a period of DAPT is considered a mandatory requirement after intracoronary stents to prevent stent thrombosis (ST), a complication associated with heart attack and a mortality rate of up to 40 %. In current clinical practice, the default strategy in most centres is 12 months’ DAPT followed by aspirin alone for life. However, the optimal duration of DAPT, particularly given the rapid iterative turnover of drug-eluting stents (DES) is the subject of discrepant evidence and clinical uncertainty. In particular, the 12-month regimen is based upon relatively weak evidence. A series of fairly small randomised trials, not powered to look specifically at ST as an endpoint, have recently indicated that there is no apparent disadvantage to shorter versus longer duration DAPT (including several trials of >12 months versus 12 months) when looking at various composite clinical endpoints. By contrast, the 9,961 patient DAPT trial, published in the New England Journal of Medicine at the end of 2014, demonstrated clinical outcome benefit, including a significantly lower rate of ST as a predefined primary endpoint, in DES patients randomised to 30 months’ DAPT compared to stopping at 12 months. Here, the authors to assess the data, including the most recent meta-analyses, in an attempt to answer the question: DAPT after DES… 12 months, longer or shorter?

Disclosure: M Sahebjalal: None. N Curzen: Unrestricted research grants from Haemonetics, St Jude Medical, Medtronic, Heartflow, Boston Scientific; Speaker fees/ consultancy: Haemonetics, St Jude Medical, Volcano, Heartflow; Unrestricted education grant: Volcano (Personal travel sponsorship). Abbott Vascular, Biosensors, Lilly/DS, St Jude Medical



Citation:Interventional Cardiology Review 2015;10(3):136–8

Correspondence: Professor Nick Curzon, E Level North Wing, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK. E:

Open access:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Antiplatelet therapy (APT) represents a major cornerstone in the secondary prevention of coronary artery disease, along with modifying patients’ risk factors. Furthermore, it has been clear, since early unsuccessful regimens, including warfarin and dypiridamole with aspirin, that it is APT that stops coronary stents from clotting off and causing stent thrombosis.1,2 Specifically, the requirement for aspirin plus a second antiplatelet drug (thus, dual-antiplatelet therapy [DAPT]) to minimise the risk of ST was quickly established.3 Initially the second agent was ticlopidine, which despite being effective at its primary task was poorly tolerated and associated with an unwelcome incidence of blood dyscrasia. Subsequently, following randomised trial evidence of beneficial clinical outcome with fewer adverse effects, clopidogrel became the P2Y12 inhibitor of choice to accompany aspirin1. Concerns about inter-individual variations in the response to clopidogrel led to the development of apparently more potent and rapidly acting agents in the form of prasugrel and ticagrelor.4,5 Specifically, the latter agents have been shown to have clinical outcome benefit compared to clopidogrel in terms of reducing some ischaemic events in heterogeneous populations of patients with acute coronary syndromes, albeit at the expense of increased bleeding.6

The concept that DAPT is necessary to prevent ST in coronary stents has been dominant for at least two decades. However, the optimal duration of that DAPT therapy always has been, and remains, uncertain and recently, in particular, has attracted considerable debate. Put simply, the question frontline interventional cardiologists face is this: how much DAPT do you need, and for how long, in order to prevent ST but minimise major bleeding?

In most interventional centres, the default DAPT regimen for most patients receiving stents consists of 12 months followed by aspirin monotherapy for life. A forensic assessment of the basis for this default unearths (perhaps surprisingly) shaky foundations. Studying the evolution of our APT to this default DAPT regimen is valuable to put the most recent challenging trial data into context. In particular, it becomes apparent that several factors have recurrently had an influence on the requirements for DAPT, including stable or acute coronary syndrome presentation, type of stent, and risk of bleeding.

Antiplatelet Therapy for Bare-metal (BMS) and First-generation Drug-eluting (DES 1) Stents

When bare-metal stents were first studied, initial therapy consisted of aspirin and dypiridamole.2 Subsequent to this, DAPT was recommended for 1 month in stable patients with BMS. The original comparative trials of DES 1 versus BMS employed DAPT for between 2 and 6 months only, admittedly in relatively stable and low-risk populations.7–9

However, as has been the case consistently since those early days, in patients with acute coronary syndromes (ACS) receiving stents there are competing indications for DAPT, since the evidence suggests a benefit from DAPT as a medical therapy in this setting. CURE was the first randomised trial to show that in a population of non-ST elevation ACS patients DAPT (using clopidogrel with aspirin) significantly decreased the rate of recurrent ischaemic events compared with aspirin monotherapy with placebo at a mean duration of therapy of 9 months.1,10 Importantly, 64 % of the 12,562 patients in this trial did not undergo revascularisation after randomisation. Specifically, there was a 20 % relative risk reduction in myocardial infarction, stroke or cardiovascular death with long-term DAPT use with no increase in life-threatening bleeds. In the CURE-PCI sub-study, there was a 25 % relative risk reduction in the composite of myocardial infarction or cardiovascular death with DAPT (≤12 months) compared with aspirin and placebo.10

It was largely based on this evidence that 12 months’ DAPT became the recommended default for stents post-ACS. However, given that there was a 4 % per year incidence of significant bleeding in the CURE study in the cohort on DAPT, there was clearly a balance to be struck between longer DAPT to reduce ischaemic events and shorter DAPT to minimise bleeding, which itself has been shown to be an independent risk factor for worse prognosis.1,10 That tension between ischaemic and bleeding events is indeed the driver for our current debate, just as it has been since stents were first implanted. In addition, the suspicion that patients receiving stents in elective, stable settings need DAPT for less time than patients presenting with ACS consistently remains a driver for reducing duration of DAPT therapy. Finally, the consistent iterative technologically-driven evolutions in the design of stents represent a further confounding factor in determining the optimal duration of DAPT.

DAPT in DES Patients – a Moving Target!

The main limitation of BMS was an exaggerated inflammatory healing response, leading to excessive neointimal proliferation and restenosis. Clinically, this led to around 10 % of patients representing with recurrent symptoms. Randomised trials demonstrating the dramatic reduction in target vessel revascularisation, due to restenosis, with DES compared with BMS has revolutionised patient care.7-9 However, the cost of this clinical benefit was a demonstrably higher risk of ST in DES1 versus BMS, which was attritional over time.11 As a result, international guidelines were changed in 2007 to indicate that all patients receiving DES should receive DAPT for “at least 12 months”.12 The default regimen was even more strongly set, albeit still based upon very little actual evidence.12

More recently, however, the continuous iteration of DES design has yielded devices with properties likely to reduce the risk of ST: thinner struts; less, or shorter duration, polymer; more sophisticated drug and dosing profiles. As a result of observational data confirming this notion, second- and third-generation DES (DES 2) have been the focus of a series of randomised trials testing shorter duration DAPT versus longer regimens.13–20 These trials are disparate in detail regarding type of stent, mix of patient presentation, duration of the DAPT regimens being compared, type of P2Y12 inhibitor and composite primary endpoint.19 However, they share some common features. First, none were powered to look at ST as a primary isolated endpoint. Second, they generally have demonstrated no advantage of a longer DAPT duration compared with shorter. Furthermore, in many cases, they demonstrated significantly higher rates of major bleeding in the longer DAPT groups.

It is notable that in some randomised trials, the duration of DAPT could be as short as 3 months with some types of DES 216–17 without any disadvantage in terms of ischaemic endpoint. The accumulated body of this evidence has pointed interventionalists towards shorter duration DAPT in DES 2 patients. This is, indeed, reflected in the 2014 ESC guidelines21 now recommend DAPT for only 6 months in stable patients receiving DES 2, but stick to 12 months’ DAPT after ACS. A seemingly logical and intuitive evolution in what we all thought we knew about DAPT with modern DES 2 was then challenged by the DAPT trial.

The DAPT Trial – Turning What We Thought We Knew on its Head

In the DAPT study 229,661 patients with a mix of elective and ACS presentations, who had undergone PCI using DES 1 and DES 2 and who had had an uneventful period of DAPT treatment for 12 months already, were then randomised to either a further 18 months of DAPT or aspirin plus placebo. There was a significant reduction in both ST (p<0.001), a specified co-primary endpoint and major adverse CV and cerebrovascular events (p<0.001) in the prolonged duration DAPT group compared with aspirin monotherapy. However, there was a significant increase in important bleeding in the 30-month DAPT group (p=0.001). Another interesting observation was that although all- cause mortality was no different between the groups, the prolonged DAPT group had a significantly higher rate of non-cardiovascular death (p=0.002).

The DAPT trial investigators concluded that the prolonged DAPT regimen (30 months) reduced ischaemic events, including ST, compared with 12 months’ DAPT. The implications of this trial are not yet as clear as they first seem. There is concern about committing all DES patients to a longer regimen associated with more severe bleeding. But also, despite the temptation to put the increased incidence of non-cardiovascular death down to statistical quirk, this raises alarm bells given the large number of patients worldwide being treated in this way. The meta-analysis by Palmerini et al., which includes the DAPT trial, just published in The Lancet,23 confirms that we should indeed take a cautious approach to a universal switch to prolonged DAPT after DES. The analysis includes more than 32,000 patients and confirms that there is a 33 % lower rate of non-cardiovascular mortality in the shorter duration DAPT arm compared with longer duration, and this actually drives a hazard ratio of 0.82 for all-cause mortality in the shorter duration group. On the other side of the coin, a meta-analysis by Elmariah et al., which involved 14 studies including the DAPT study, showed that extended-duration was not associated with a difference in the risk of all-cause, cardiovascular or non- cardiovascular death compared with aspirin alone or short-duration.24

DAPT after DES – What Should We Do Now?

Although the evidence apparently presents a chaotic and discrepant picture, some themes regarding our DAPT strategy for DES patients are manifest. First, that if DAPT is used for longer, the risk of ischaemic events, including ST, will be reduced. Second, that this reduction will be at the expense of increased bleeding. Third, strong circumstantial evidence suggests that if DAPT is used for more than a year, non-CV mortality is higher – perhaps because of the excess in important bleeding.

Taking these concepts together, it seems sensible to stick, for now, with a default of 12 months’ DAPT for most patients, pending further specific data.

DAPT after DES – What Do We Need to Know for the Future?

In order to make progress in this field, we need to address more precisely some unanswered questions. These are questions that cannot be answered in trials that recruit patients with a variety of elective and ACS presentations using different generations of stent and different DAPT constituents. We need answers to these questions via appropriately powered randomised trials:

  • Using specific DES 2 (i.e. only one type in each trial), can DAPT be safely employed for 6, 3 or 1 month(s) in elective patients?
  • Using specific DES 2, can DAPT be safely employed for 6 or even 3 months in ACS patients?
  • Do we actually need DAPT anyway? The results of trials like GLOBAL LEADERS,25 randomising DES patients to ticagrelor alone compared with DAPT after a certain period of aspirin plus ticagrelor, could revolutionise our thinking about this field completely.

Finally, what shines out of a forensic assessment of the current evidence about DAPT after DES is this: the concept that we can have wholesale strategies for APT for large groups of patients is fundamentally flawed. The real challenge is to develop personalised pathways of care that take into account individual risk of ischaemic events, bleeding and, probably, also their response to APT using point-of-care tests of platelet reactivity.26-27 It is time to discard our palpably inadequate “one-size- fits-all” approach and develop patient-specific strategies. Such an individualised approach might well eliminate many of the adverse effects we currently witness.


  1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494–502.
    Crossref | PubMed
  2. Serruys PW, de Jaegere P, Kiemeneij F. A Comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489–95.
    Crossref | PubMed
  3. Hobson A, Curzen N. Current status of oral antiplatelet therapies. In: Redwood S, Curzen N (eds) Thomas Oxford Textbook of Interventional Cardiology. Oxford: Oxford University Press, 2010; 379–94.
  4. Wiviott S, Braunwald E. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–15.
    Crossref | PubMed
  5. Wallentin L, Becker RC. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–57.
    Crossref | PubMed
  6. Curzen N. Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel. Heart 2012;98:1617–9.
    Crossref | PubMed
  7. Serruys PW, Degertekin M. Intravascular ultrasound findings in the multicentre, randomised, double-blind RAVEL (RAndomised study with the sirolimus-eluting VElocityballoon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798–803.
  8. Moses JW, Leon MB. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315–23.
    Crossref | PubMed
  9. Stone GW, Ellis SG. One-year clinical results with the slow- release, polymer-based, paclitaxel-eluting TAXUS stent The TAXUS-IV Trial. Circulation 2004;109:1942–7.
    Crossref | PubMed
  10. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527–33.
    Crossref | PubMed
  11. Lagerqvist B, James, Stefan. Long-term outcomes with drug- eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009–19
    Crossref | PubMed
  12. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. Circulation 2007;116(7):e148–304.
    Crossref | PubMed
  13. Lee CW, Ahn JM, Park DW, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomised, controlled trial. Circulation 2014 21;129:304–12.
    Crossref | PubMed
  14. Feres F, Costa RA, Abizaid A, et al. and the OPTIMIZE Trial Investigators. Three versus twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomised trial. JAMA 2013;310:2510–22.
    Crossref | PubMed
  15. Kim BK, Hong MK, Shin DH, et al. and the RESET Investigators. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of three-month dual antiplatelet therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012;60:1340–48.
    Crossref | PubMed
  16. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drug-eluting stents implantation followed by six versus 12-month dual antiplatelet therapy – the SECURITY randomised clinical trial. J Am Coll Cardiol 2014;64:2086–97.
    Crossref | PubMed
  17. Gwon HC, Hahn JY, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of Xience/Promus versus cypher to reduce late loss after stenting (EXCELLENT) randomised, multicentre study. Circulation 2012;125:505–13.
  18. Valgimigli M, Campo G, Monti M, et al. and the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual antiplatelet therapy after coronary stenting: a randomised multicentre trial. Circulation 2012;125:2015–26.
    Crossref | PubMed
  19. Elmariah S, Mauri L, Doros G. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015 Feb 28;385:2332–3.
    Crossref | PubMed
  20. Zhang T, Shen L, Hu L, He B. Optimal duration of dual- antiplatelet therapy following drug-eluting stent implantation: a meta-analysis. J Clin Pharmacol 2013;53:345–51.
    Crossref | PubMed
  21. Hamm CW1, Bassand JP, Agewall S, et al. and the ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999–3054.
    Crossref | PubMed
  22. Mauri L, Kereiake DJ, Yeh RW. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–66.
    Crossref | PubMed
  23. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended-duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015;385(9985):2371–82.
    Crossref | PubMed
  24. Elmariah S, Mauri L, Doros G, et al. Extended-duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015:380:792–8.
    Crossref | PubMed
  25. GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation ( Identifier: NCT01813435). Available at: ct2/show/NCT01813435 (accessed 24 August 2015).
  26. Curzen N. Prolonged antiplatelet therapy after drug-eluting stents. Lancet 2015;385:2332–3.
    Crossref | PubMed
  27. Jiabei L, Zhao J, Wenyun G, Guozhu C. Tailored antiplatelet therapy and clinical adverse outcomes. Heart 2014;100:41–6.
    Crossref | PubMed